Neil Clark, chief executive of Destiny Pharma, spoke to Proactive London about the company's two lead assets.
Clark said Destiny Pharma is focused on preventing infections and highlights the benefits of prevention.
It has two differentiated assets, both focused on prevention of serious bacterial infections.